用MK-991（L-743,872）治疗组织胞浆菌病。
Treatment of histoplasmosis with MK-991 (L-743,872).
作者信息
Graybill J R, Najvar L K, Montalbo E M, Barchiesi F J, Luther M F, Rinaldi M G
机构信息
The University of Texas Health Science Center at San Antonio, 78284, USA.
出版信息
Antimicrob Agents Chemother. 1998 Jan;42(1):151-3. doi: 10.1128/AAC.42.1.151.
Abstract
BALB/c nu/+ immunocompetent and athymic (nu/nu) mice were infected intravenously with yeast cells of Histoplasma capsulatum. Mice were either given water (controls) intraperitoneally (i.p.) or given MK-991 i.p. once daily or twice daily. Protection was measured as prolonged survival or reduction in tissue counts. MK-991 was protective in immunocompetent mice, prolonging survival and reducing counts in spleen and livers at a dose as low as 0.05 mg/kg of body weight/day. MK-991 was modestly effective in athymic mice at a higher dose, 5 mg/kg/day. These studies suggest that MK-991 may be appropriate for clinical development in histoplasmosis.
摘要
将具有免疫活性的BALB/c裸合（nu/+）小鼠和无胸腺（nu/nu）小鼠通过静脉注射荚膜组织胞浆菌的酵母细胞进行感染。小鼠腹腔内（i.p.）要么给予水（作为对照），要么每天一次或每天两次腹腔内给予MK - 991。通过延长生存期或减少组织菌数来衡量保护作用。MK - 991对具有免疫活性的小鼠具有保护作用，在低至0.05毫克/千克体重/天的剂量下可延长生存期并减少脾脏和肝脏中的菌数。MK - 991在较高剂量（5毫克/千克/天）时对无胸腺小鼠有一定效果。这些研究表明，MK - 991可能适用于组织胞浆菌病的临床开发。
相似文献
1
Treatment of histoplasmosis with MK-991 (L-743,872).用MK-991（L-743,872）治疗组织胞浆菌病。
Antimicrob Agents Chemother. 1998 Jan;42(1):151-3. doi: 10.1128/AAC.42.1.151.
2
Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model.在小鼠模型中，棘白菌素类药物卡泊芬净与两性霉素B治疗肺部感染组织胞浆菌病的比较。
Antimicrob Agents Chemother. 2000 Jul;44(7):1850-4. doi: 10.1128/AAC.44.7.1850-1854.2000.
3
Combined therapy with amphotericin B and caspofungin in an experimental model of disseminated histoplasmosis.两性霉素B与卡泊芬净联合治疗播散性组织胞浆菌病的实验模型
Rev Invest Clin. 2009 Jan-Feb;61(1):4-10.
4
Suppression of cryptococcosis and histoplasmosis by ketoconazole in athymic nude mice.酮康唑对无胸腺裸鼠隐球菌病和组织胞浆菌病的抑制作用。
J Infect Dis. 1980 Jan;141(1):76-80. doi: 10.1093/infdis/141.1.76.
5
Efficacy of nikkomycin Z in the treatment of murine histoplasmosis.尼克霉素Z治疗小鼠组织胞浆菌病的疗效。
Antimicrob Agents Chemother. 1998 Sep;42(9):2371-4. doi: 10.1128/AAC.42.9.2371.
6
Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii.半合成肺孢子菌素MK-991（L-743,872）在卡氏肺孢子虫小鼠模型中的疗效。
Antimicrob Agents Chemother. 1998 Aug;42(8):1985-9. doi: 10.1128/AAC.42.8.1985.
7
Investigation of the efficacy of micafungin in the treatment of histoplasmosis using two North American strains of Histoplasma capsulatum.采用北美荚膜组织胞浆菌两个株系对米卡芬净治疗组织胞浆菌病的疗效进行研究。
Antimicrob Agents Chemother. 2011 Sep;55(9):4447-50. doi: 10.1128/AAC.01681-10. Epub 2011 Jun 13.
8
In vitro antifungal susceptibility profile and correlation of mycelial and yeast forms of molecularly characterized Histoplasma capsulatum strains from India.印度分子特征明确的荚膜组织胞浆菌菌株菌丝体和酵母形式的体外抗真菌药敏谱及其相关性
Antimicrob Agents Chemother. 2014 Sep;58(9):5613-6. doi: 10.1128/AAC.02973-14. Epub 2014 Jun 30.
9
Treatment of murine Candida krusei or Candida glabrata infection with L-743,872.用L-743,872治疗小鼠克鲁斯念珠菌或光滑念珠菌感染。
Antimicrob Agents Chemother. 1997 Sep;41(9):1937-9. doi: 10.1128/AAC.41.9.1937.
10
A proposal for antifungal epidemiological cut-off values against Histoplasma capsulatum var. capsulatum based on the susceptibility of isolates from HIV-infected patients with disseminated histoplasmosis in Northeast Brazil.基于巴西东北部 HIV 感染并发播散性组织胞浆菌病患者分离株的药敏结果，提出荚膜组织胞浆菌荚膜变种的抗真菌流行病学折点值建议。
Int J Antimicrob Agents. 2018 Aug;52(2):272-277. doi: 10.1016/j.ijantimicag.2018.03.017. Epub 2018 Mar 26.
引用本文的文献
1
Effect of Cinnamaldehyde on C. albicans cell wall and (1,3)- β - D-glucans in vivo.肉桂醛对体内白色念珠菌细胞壁和（1,3）-β-D-葡聚糖的影响。
BMC Complement Med Ther. 2022 Jan 31;22(1):32. doi: 10.1186/s12906-021-03468-y.
2
Effects of Cinnamaldehyde on the Cell Wall of and Its Application in Treating Mice with Invasive Pulmonary Aspergillosis.肉桂醛对烟曲霉细胞壁的影响及其在侵袭性肺曲霉病小鼠治疗中的应用
Evid Based Complement Alternat Med. 2018 Oct 4;2018:5823209. doi: 10.1155/2018/5823209. eCollection 2018.
3
Disseminated histoplasmosis in an immunocompetent patient from an endemic area: A case report.来自疫区的免疫功能正常患者的播散性组织胞浆菌病：病例报告
Medicine (Baltimore). 2018 Jul;97(29):e11486. doi: 10.1097/MD.0000000000011486.
4
In vitro antifungal susceptibility profile and correlation of mycelial and yeast forms of molecularly characterized Histoplasma capsulatum strains from India.印度分子特征明确的荚膜组织胞浆菌菌株菌丝体和酵母形式的体外抗真菌药敏谱及其相关性
Antimicrob Agents Chemother. 2014 Sep;58(9):5613-6. doi: 10.1128/AAC.02973-14. Epub 2014 Jun 30.
5
Identification of an aminothiazole with antifungal activity against intracellular Histoplasma capsulatum.鉴定一种具有抗细胞内荚膜组织胞浆菌活性的氨基噻唑。
Antimicrob Agents Chemother. 2013 Sep;57(9):4349-59. doi: 10.1128/AAC.00459-13. Epub 2013 Jul 1.
6
Micafungin in the treatment of invasive candidiasis and invasive aspergillosis.米卡芬净治疗侵袭性念珠菌病和侵袭性曲霉病。
Infect Drug Resist. 2008;1:63-77. Epub 2009 Jan 12.
7
Investigation of the efficacy of micafungin in the treatment of histoplasmosis using two North American strains of Histoplasma capsulatum.采用北美荚膜组织胞浆菌两个株系对米卡芬净治疗组织胞浆菌病的疗效进行研究。
Antimicrob Agents Chemother. 2011 Sep;55(9):4447-50. doi: 10.1128/AAC.01681-10. Epub 2011 Jun 13.
8
Caspofungin: the first agent available in the echinocandin class of antifungals.卡泊芬净：棘白菌素类抗真菌药物中的首个可用药物。
Proc (Bayl Univ Med Cent). 2002 Jan;15(1):97-9. doi: 10.1080/08998280.2002.11927822.
9
In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms.米卡芬净（FK463）对双相真菌的体外抗真菌活性：酵母样和菌丝体形式的比较。
Antimicrob Agents Chemother. 2003 Apr;47(4):1376-81. doi: 10.1128/AAC.47.4.1376-1381.2003.
10
Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).评价肉汤微量稀释法检测参数及琼脂扩散Etest法检测曲霉属对醋酸卡泊芬净（MK-0991）敏感性的方法。
J Clin Microbiol. 2003 Jan;41(1):403-9. doi: 10.1128/JCM.41.1.403-409.2003.
本文引用的文献
1
Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-beta-D-glucan synthase.西洛芬净体内疗效与其对烟曲霉（1,3）-β-D-葡聚糖合酶活性的相关性。
FEMS Microbiol Lett. 1993 Apr 1;108(2):133-7. doi: 10.1111/j.1574-6968.1993.tb06088.x.
2
Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome.伊曲康唑预防获得性免疫缺陷综合征患者组织胞浆菌病复发的研究。
Ann Intern Med. 1993 Apr 15;118(8):610-6. doi: 10.7326/0003-4819-118-8-199304150-00006.
3
Oral azole drugs as systemic antifungal therapy.口服唑类药物作为全身性抗真菌治疗。
N Engl J Med. 1994 Jan 27;330(4):263-72. doi: 10.1056/NEJM199401273300407.
4
Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome.
Am J Med. 1994 Jun;96(6):504-8. doi: 10.1016/0002-9343(94)90089-2.
5
Histoplasmosis: recognition and treatment.组织胞浆菌病：识别与治疗
Clin Infect Dis. 1994 Aug;19 Suppl 1:S19-27. doi: 10.1093/clinids/19.supplement_1.s19.
6
The lipopeptide antimycotic, cilofungin modulates the incorporation of glucan-associated proteins into the cell wall of Candida albicans.脂肽抗真菌药西洛芬净可调节葡聚糖相关蛋白掺入白色念珠菌的细胞壁。
J Antimicrob Chemother. 1994 Jun;33(6):1137-46. doi: 10.1093/jac/33.6.1137.
7
Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group.伊曲康唑治疗获得性免疫缺陷综合征患者播散性组织胞浆菌病。艾滋病临床试验组。
Am J Med. 1995 Apr;98(4):336-42. doi: 10.1016/s0002-9343(99)80311-8.
8
Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis.水溶性半合成肺念珠菌素L-733,560的抗真菌活性增强，这是由于其对细胞壁合成的抑制作用增强所致。
Antimicrob Agents Chemother. 1994 Dec;38(12):2750-7. doi: 10.1128/AAC.38.12.2750.
9
Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.利用播散性曲霉病、念珠菌病和隐球菌病小鼠模型对水溶性棘白菌素类似物L-733560、L-705589和L-731373进行评估。
Antimicrob Agents Chemother. 1995 May;39(5):1077-81. doi: 10.1128/AAC.39.5.1077.
10
In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373.新型水溶性L-705589与L-731373杂交体——抗真菌药L-733560的体外评价
Antimicrob Agents Chemother. 1995 May;39(5):1070-6. doi: 10.1128/AAC.39.5.1070.
Zotero 插件